Results 51 to 60 of about 7,115 (194)

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS

Российский кардиологический журнал, 2011
Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension ...
J. M. Neutel, W. J. Elliott, J. L. Izzo, C. L. Chen, H. N. Masonson   +4 more
doaj  

Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke

International Journal of Hypertension, 2019
Background. Elevated blood pressure (BP) in the acute phase of ischemic stroke is associated with heightened risk of early disability and death. However, whether BP-lowering in this setting is beneficial and the exact levels at which BP should be ...
Eleni Georgianou, Panagiotis I. Georgianos, Konstantinos Petidis, Konstantinos Markakis, Ioanna Zografou, Asterios Karagiannis   +5 more
doaj   +1 more source

Self‐Care Behaviors in Osteoporosis: A Cross‐Cultural Study Using Multidimensional Analysis of Textual Data

Journal of Nursing Scholarship, Volume 58, Issue 5, September 2026.
ABSTRACT Introduction Osteoporosis is a chronic skeletal condition that significantly affects daily life and may benefit from adequate self‐care. The Middle‐Range Theory of Self‐Care of Chronic Illness conceptualizes self‐care as a naturalistic process encompassing maintenance, monitoring, and management, also shaped by contextual and cultural factors.
Chiara Tedesco, Vicente Bernalte‐Martí, Adela Melgarejo Uréndez, Arantxa Conesa, María Desamparados Bernat‐Adell, Mara Tormen, Gianluca Pucciarelli, Ercole Vellone, Maddalena De Maria, Emanuela Basilici Zannetti, Noemi Cittadini, Annalisa Pennini, Umberto Tarantino, Rosaria Alvaro, Mariachiara Figura   +14 more
wiley   +1 more source

Association Between Disruption of Blood Pressure Circadian Rhythm and Prognosis After Acute Anterior Myocardial Infarction

Clinical Cardiology, Volume 49, Issue 8, August 2026.
This study retrospectively analyzed the characteristics of blood pressure rhythm after emergency PCI for patients with anterior STEMI, discovering the burden of disrupted BP circadian rhythm. The reverse dipper BP rhythm may serve as an independent factor of MACE.
Yangge Shao, Yajuan Yang, Chao Wang, Zhiming Yu, Ruxing Wang   +4 more
wiley   +1 more source

Clinical efficacy and tolerability of olmesartan.

, 2004
BACKGROUND Olmesartan medoxomil is an angiotensin II receptor antagonist that selectively and competitively inhibits the angiotensin II type 1 receptor.
Brunner HR
core   +1 more source

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study

Vascular Health and Risk Management, 2009
Vivencio Barrios1, Carlos Escobar1, Alberto Calderon2, Michael Böhm31Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain; 2Primary Care Center Rosa de Luxemburgo, Madrid, Spain; 3Klinik für Innere Medizin III ...
Vivencio Barrios, Carlos Escobar, Alberto Calderon, et al   +3 more
doaj  

Exploring Risks of Adverse Drug Events From Single Drug to Three‐Drug Combination

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Use of three‐drug combinations is common and could increase the risk of adverse drug events (ADEs). Signals of ADEs from three‐drug combinations could be identified from real‐world data, and the risks of ADEs from single drug exposure to three‐drug combination exposure could be illustrated by a graphic model.
Yi Shi, Anna Sun, Chien‐Wei Chiang, Yuedi Yang, Katherine M. Hunold, Jing Xu, Mu Shan, Allison Lu, Massimiliano Russo, Jeffrey M. Caterino, Michael T. Eadon, Lang Li, Jing Su, Macarius Donneyong, Pengyue Zhang   +14 more
wiley   +1 more source

Investigation of hydrolysis of olmesartan medoxomil in different pH buffers by simultaneously measuring olmesartan medoxomil and olmesartan

PLOS One
Olmesartan medoxomil (OLM) is an ester prodrug of olmesartan (OL) developed to overcome the poor permeability of OL. OLM is an angiotensin receptor blocker and is commonly used to treat hypertension. However, OLM has low water solubility and low bioavailability of 26%. It is understood that OLM is unstable in aqueous media; however, this hydrolysis has
Lauren Landry, Xiaowei Dong
openaire   +3 more sources

Skin Acceptability of a Topical Cream Containing Zinc Oxide, Zinc Gluconate, Taurine and Panthenol in Females With Urinary Incontinence

Journal of Cosmetic Dermatology, Volume 25, Issue 8, August 2026.
ABSTRACT Background Incontinence‐associated dermatitis (IAD) can be exacerbated by friction and occlusion from a diaper/incontinence pad. Skin barrier function in IAD can be preserved through humectant and emollient‐containing protective agents. Aims To investigate the efficacy, skin acceptability, and cosmetic qualities of a cream containing zinc ...
Leonardo Celleno, Linda Landini, Dalia Mostafa Kamal, Fabrizio Mazzicone   +3 more
wiley   +1 more source

Valsartan Reduces Myocardial Ischemia–Reperfusion Injury by Inhibiting Ferritinophagy‐Mediated Ferroptosis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 13, July 2026.
ABSTRACT Revascularisation is the key therapeutic strategy for acute myocardial infarction (AMI). However, the opening of the ‘culprit artery’ is accompanied by myocardial ischemia–reperfusion injury (IRI), partially offsetting the benefits of revascularisation. At present, effective methods to alleviate myocardial IRI are lacking.
Xumin Wang, Bixue Zhang, Xin Li, Qianqian Xu, Yuanliang Sun, Kaikai Zhao, Xintao Zhou, Yuhong Wu, Zheng Cheng   +8 more
wiley   +1 more source